drugset / Trial / NCT07012980
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Phase 2
Not yet recruiting
38 enrolled
Shanghai Zhongshan Hospital
BeiGene · collabHoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |